P Jeffrey Conn Selected Research

N- (3- oxo- 3- (4- (pyridin- 4- yl)piperazin- 1- yl)propyl)benzo(c)(1,2,5)thiadiazole- 4- sulfonamide

3/2012	Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.
8/2009	A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

P Jeffrey Conn Research Topics

Disease

69	Schizophrenia (Dementia Praecox) 01/2022 - 02/2002
31	Parkinson Disease (Parkinson's Disease) 08/2021 - 06/2002
18	Alzheimer Disease (Alzheimer's Disease) 12/2020 - 10/2008
12	Catalepsy 01/2021 - 10/2008
7	Central Nervous System Diseases (CNS Diseases) 08/2021 - 07/2007
7	Nervous System Diseases (Neurological Disorders) 12/2019 - 09/2008
7	Cocaine-Related Disorders (Cocaine Addiction) 01/2017 - 03/2010
6	Psychotic Disorders (Schizoaffective Disorder) 03/2015 - 11/2003
5	Brain Diseases (Brain Disorder) 12/2019 - 02/2015
5	Dyskinesias (Dyskinesia) 01/2016 - 12/2009
4	Neurodevelopmental Disorders 01/2022 - 01/2017
4	Rett Syndrome (Rett's Disorder) 01/2022 - 01/2017
4	Neurobehavioral Manifestations 01/2021 - 05/2010
4	Seizures (Absence Seizure) 01/2019 - 08/2009
3	Movement Disorders (Movement Disorder) 08/2021 - 11/2014
3	Dystonia (Limb Dystonia) 08/2021 - 08/2009
3	Substance-Related Disorders (Drug Abuse) 01/2019 - 11/2012
3	Fragile X Syndrome (Martin Bell Syndrome) 01/2016 - 01/2011
3	Autistic Disorder (Autism) 01/2016 - 09/2012
3	Mental Disorders (Mental Disorder) 01/2010 - 12/2005
2	Anhedonia 01/2020 - 01/2019
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2019 - 03/2015
2	Disease Progression 01/2018 - 12/2009
2	Cognitive Dysfunction 01/2016 - 05/2013
2	Bipolar Disorder (Manic Depressive Psychosis) 11/2015 - 01/2015
2	Choriocarcinoma 11/2004 - 10/2003
1	Opioid-Related Disorders (Opiate Addiction) 01/2022
1	Depressive Disorder (Melancholia) 01/2021
1	Treatment-Resistant Depressive Disorder 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2020
1	Mood Disorders (Mood Disorder) 01/2020
1	Binge-Eating Disorder (Binge Eating Disorder) 01/2019
1	Obesity 01/2019
1	Huntington Disease (Huntington's Disease) 01/2018
1	Alcoholism (Alcohol Abuse) 01/2018
1	Lubs X-linked mental retardation syndrome 01/2018
1	Dementia (Dementias) 01/2017
1	Syndrome (Syndromes) 01/2017
1	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 10/2016
1	Inflammation (Inflammations) 01/2016

Drug/Important Bio-Agent (IBA)

37	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2022 - 02/2002
30	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2022 - 01/2008
16	Glutamic Acid (Glutamate)FDA Link 01/2022 - 12/2005
15	Pharmaceutical PreparationsIBA 12/2019 - 02/2002
13	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 02/2002
11	Haloperidol (Haldol)FDA LinkGeneric 01/2021 - 11/2008
11	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2017 - 02/2002
10	Cholinergic Agents (Cholinergics)IBA 12/2020 - 02/2002
7	metabotropic glutamate receptor 2IBA 01/2018 - 02/2006
7	N-Methylaspartate (NMDA)IBA 12/2016 - 02/2002
6	LigandsIBA 01/2022 - 12/2009
6	Muscarinic M4 ReceptorIBA 10/2018 - 01/2014
6	Glutamate Receptors (Glutamate Receptor)IBA 12/2016 - 01/2003
6	Metabotropic Glutamate 5 ReceptorIBA 10/2016 - 10/2013
6	metabotropic glutamate receptor 4IBA 01/2016 - 08/2003
6	Levodopa (L Dopa)FDA LinkGeneric 01/2016 - 12/2009
5	Neurotransmitter Agents (Neurotransmitter)IBA 08/2021 - 12/2011
4	Muscarinic M1 ReceptorIBA 01/2019 - 11/2014
4	Dopamine (Intropin)FDA LinkGeneric 01/2019 - 02/2002
4	metabotropic glutamate receptor 3 (mGluR3)IBA 01/2015 - 07/2006
3	Methyl-CpG-Binding Protein 2IBA 01/2022 - 01/2017
3	metabotropic glutamate receptor 7IBA 01/2021 - 03/2010
3	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2020 - 12/2012
3	Proteins (Proteins, Gene)FDA Link 10/2018 - 12/2011
3	Amphetamine (Amfetamine)FDA LinkGeneric 10/2018 - 07/2014
3	Cocaine (Cocaine HCl)IBA 01/2017 - 01/2011
3	Reserpine (Serpasil)FDA Link 03/2013 - 11/2008
2	Muscarinic AntagonistsIBA 08/2021 - 11/2014
2	Antidepressive Agents (Antidepressants)IBA 01/2021 - 01/2020
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021 - 02/2002
2	Cholinergic ReceptorsIBA 01/2019 - 12/2012
2	benzocycloheptapyridineIBA 01/2018 - 01/2013
2	Dizocilpine Maleate (Dizocilpine)IBA 01/2018 - 03/2016
2	Phencyclidine (Angel Dust)IBA 10/2017 - 02/2002
2	Clozapine (Clozaril)FDA LinkGeneric 03/2016 - 11/2003
2	N-(3-chlorophenyl)picolinamideIBA 08/2015 - 02/2012
2	Cholinergic Antagonists (Anticholinergics)IBA 11/2014 - 05/2010
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 11/2012 - 11/2004
2	N- (3- oxo- 3- (4- (pyridin- 4- yl)piperazin- 1- yl)propyl)benzo(c)(1,2,5)thiadiazole- 4- sulfonamideIBA 03/2012 - 08/2009
2	VU 0155041IBA 09/2009 - 11/2008
2	Glycine Plasma Membrane Transport ProteinsIBA 11/2004 - 10/2003
1	VU6019650IBA 01/2022
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 11/2021
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2021
1	Ketamine FDA LinkGeneric 01/2021
1	VU0652957IBA 03/2019
1	Hydroxyl RadicalIBA 09/2018
1	AminesIBA 01/2018
1	EndocannabinoidsIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	VU0467485IBA 02/2017
1	VU0476406IBA 01/2017
1	Neuroprotective AgentsIBA 01/2017
1	Divalent CationsIBA 05/2016
1	PirenzepineIBA 05/2016
1	5- amino- 3,4- dimethyl- N- (4- ((trifluoromethyl)sulfonyl)benzyl)thieno(2,3- c)pyridazine- 6- carboxamideIBA 03/2016
1	Hypnotics and Sedatives (Sedatives)IBA 03/2016
1	VU0486321IBA 02/2016

Therapy/Procedure

12	Therapeutics 01/2022 - 06/2002
3	Drug Therapy (Chemotherapy) 01/2018 - 03/2010